Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents

Am J Hematol. 2021 May 1;96(5):E140-E143. doi: 10.1002/ajh.26117. Epub 2021 Feb 18.

Authors

Tamer A Othman¹, Matthew Mei², Jianying Zhang², Ibrahim Aldoss², Anthony Stein², Stephen J Forman², Guido Marcucci², Vinod Pullarkat²

Affiliations

¹ University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
² Department of Hematology and HCT, Gehr Center for Leukemia Research, City of Hope, Duarte, CA, USA.

PMID: 33524204
DOI: 10.1002/ajh.26117

No abstract available

Publication types

Letter

MeSH terms

Abnormal Karyotype
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
DNA Methylation / drug effects
Female
Humans
Leukemia, Myeloid, Acute / blood
Leukemia, Myeloid, Acute / complications
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Male
Middle Aged
Mutation
Neoplasm Proteins / genetics
Neoplasm Proteins / metabolism
Prognosis
Receptors, Thrombopoietin / metabolism
Remission Induction
Retrospective Studies
Sulfonamides / administration & dosage
Thrombocytopenia / etiology
Thrombocytosis / chemically induced*
Thrombopoietin / metabolism
Treatment Outcome

Substances

Bridged Bicyclo Compounds, Heterocyclic
Neoplasm Proteins
Receptors, Thrombopoietin
Sulfonamides
MPL protein, human
Thrombopoietin
venetoclax